Injecting drug use among inmates in Norwegian prisons

Knut Boe Kielland 1, Anne Bukten 2

1 Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Innlandet Hospital Trust, Norway 2 Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo

BACKGROUND

- People who inject drugs (PWID) have several barriers to antiviral treatment for chronic hepatitis C (CHC). Treatment during incarceration may be a way of overcoming some of these barriers. In 2014 the number of persons starting prison terms in Norway was 6,576 of which around 40% would serve more than 90 days in prison. About 50% of PWID in Norway have CHC. The total number of individuals with CHC in Norway is supposed to be about 20,000. The objectives of the present study were to:
  - Explore injecting drug use (IDU) among prisoners in Norway lifetime, last six months before incarceration, and during incarceration
  - Estimate the potential for antiviral treatment of CHC during incarceration.

METHODS

- The study was based on a large survey on mental health and substance abuse in Norwegian prisons performed 2013 and 2014, managed by one of the authors (AB) [1]. Prisons from 57 of the totally 63 prison units in Norway participated in the survey. Inclusion criteria were age over 18 years and sufficient understanding of Norwegian, English, French, Russian or German. Inmates were recruited based on the availability and willingness to participate. For the estimation of the prevalence of CHC among PWID in prisons, results from studies on other PWID populations in Norway have been applied.

RESULTS

- Of 1499 participating prisoners (males 93%), 431 (29%) reported IDU lifetime (PWID) (Figure 1).
- 75% of lifetime PWID had injected drugs last 6 months before the incarceration (Figure 2).
- IDU during past incarcerations were reported by 143/431 (33%) of lifetime PWID, 10% of all inmates.
- IDU during incarceration with syringe or needle previously used by others at least once, were reported by 95 (66% of those who had injected drugs in prison, and 22% of lifetime injectors) (Figure 3).
- About 900 inmates with CHC may possibly initiate DAA-treatment in prison during one year.
- For about 300 it would be possible to complete the medication before the release from incarceration (Figure 4).

Assumptions:
  - The fraction of inmates with lifetime IDU experience (PWID) in Norwegian prisons is the same as among the participants in the survey.
  - About 50% of Norwegian PWID have CHC.

CONCLUSION

- If the studied inmates were representative of the total prison population, prisons may be an important arena for antiviral treatment of CHC among PWID.

References


Disclosures: Kielland has given sponsored lectures for MSD and Abbvie. Bukten declares no conflict of interest.